Nebulized corticosteroids in asthma and COPD. An Italian appraisal

Respiratory Care

Volumn 57, Issue 7, 2012, Pages 1161-1174

  Melani, Andrea S ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Beclomethasone dipropionate; Budesonide inhalation suspension; Chronic obstructive pulmonary disease; Chronic persistent asthma; Flunisolide; Fluticasone propionate; Inhaled corticosteroids; Jet nebulizers; Nebulization; Nebulizer therapy; Ultrasonic nebulizers

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE PROPIONATE; MONTELUKAST; PLACEBO; PREDNISOLONE;

AEROSOL; AREA UNDER THE CURVE; ASTHMA; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; IN VIVO STUDY; NEBULIZATION; REVIEW; SINGLE DRUG DOSE; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; WHEEZING;

ADMINISTRATION, INHALATION; ANDROSTADIENES; ASTHMA; BECLOMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84863896162     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01414     Document Type: Review

References (214)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2007. http://www.ginasthma.com. Accessed April 25, 2012
2. National Heart, Lung and Blood Institute. Expert panel Report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD: NHLBI; 2007. http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.pdf. Accessed April 25, 2012
3. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Goetz M, et al. Diagnosis and treatment of asthma in childhood: the PRACTALL consensus report. Allergy 2008;63(1):5-34.
4. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000;(2):CD001107.
5. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006;354(19):1998-2005.
6. Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr, et al; for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing J Allergy Clin Immunol 2008;122(6):1127-1135.
7. Brand PL, Baraldi E, Bisgaard H; on behalf of the ERS Task Force. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence based approach. Eur Respir J 2008; 32(4):1096-1110.
8. Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 2009; 123(2):e519-e525.
9. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009;34(1):13-16.
10. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009;34(1):10-12.
11. Puhan MA, Bachmann LM, Kelijnen J, ter Riet G, Kessels AG. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009;7:2.
12. Rodrigo GJ. Inhaled corticosteroids as rescue medication in acute severe asthma. Expert Rev Clin Immunol 2008;4(6):723-729.
13. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/ American College of Asthma, Allergy, and Immunology. Chest 2005;127(1):335-371.
14. Celli BR, MacNee W, committee members of ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6): 932-946.
15. Global Initiative for Chronic Obstructive Lung disease. Global strategy for the diagnosis, management and prevention of COPD. Updated 2006. http://www.goldcopd.com Accessed April 25, 2012
16. British Thoracic Society Nebuliser Project Group. Current best practice for nebuliser treatment. Thorax 1997;52(Suppl 2):S1-S24.
17. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, et al. on behalf of a European Respiratory Society Task Force on the use of nebulizers. European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 2001;18(2):228-242.
18. Vermeire P. European trends in inhalation therapy. Eur Respir Rev 1994;4(18):89-91.
19. Lavorini F, Corrigan CJ, Barnes PJ, Dekhuijzen PR, Levy ML, Pedersen S, et al. on behalf of Aerosol Drug Management Improvement Team. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med 2011;105(7):1099-1103.
20. Melani AS, Pirrelli M, Sestini P, DelDonno M, Bonavia M, Canessa P, et al; on behalf of the Associazione Italiana Pneumologi Ospedalieri Educational Group. GENebu Project. Equipment and drugs used for home nebulizer therapy in Italy. Monaldi Arch Chest Dis 2002;57(5-6):231-236.
21. Clavenna A, Rossi E, Berti A, Pedrazzi G, DeRosa M, Bonati M; ARNO Working Group. Inappropriate use of antiasthmatic drugs in the Italian paediatric population. Eur J Clin Pharmacol 2003;59(7): 565-569.
22. Szefler SJ. Clinical need for a nebulized corticosteroid. J Allergy Clin Immunol 1999;104(Suppl 4):162S-168S
23. Marcus P. The role of nebulized inhaled corticosteroid therapy in adult patients with asthma and chronic obstructive pulmonary disease. Adv Ther 2005;22(4):407-418.
24. Leflein J, Brown E, Hill M, Kelly HW, Loffert TD, Nelson HS, Szefler SJ. Delivery of glucocorticoids by jet nebulization: aerosol characteristics and output. J Allergy Clin Immunol 1995;95(5 Pt 1): 944-949.
25. Berlinski A, Waldrep JC. Aerosol characterization of nebulized intranasal glucocorticoid formulations. J Aerosol Med 2001;14(2): 237-244.
26. Konig P, Shatley M, Levine C, Mawhinney TP. Clinical observations of nebulized flunisolide in infants and young children with asthma and bronchopulmonary dysplasia. Pediatr Pulmonol 1992; 13(4):209-214.
27. Allen ED, Whitaker ER, Ryu G. Six-week trial of nebulized flunisolide nasal spray: efficacy in young children with moderately severe asthma. Pediatr Pulmonol 1997;24(6):397-405.
28. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS. Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis. Drugs 1980;19(6):397-441.
29. Jarvis B, Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages _ 500 _cg/day in adults and adolescents with mild to moderate asthma. Drugs 1999;57(5):769-803.
30. Berger WE. Budesonide inhalation suspension for the treatment of asthma in infants and children. Drugs 2005;65(14):1973-1989.
31. Nicolini G, Cremonesi G, Melani AS. Inhaled corticosteroid therapy with nebulized beclomethasone dipropionate. Pulm Pharmacol Ther 2010;23(3):145-155.
32. Edman P. Pharmaceutical formulations-suspensions and solutions. J Aerosol Med 1994;7(Suppl 1):3S-6S
33. Keller M, Jauernig J, Lintz FC, Knoch M. Nebulizer nanosuspensions: important device and formulation interactions. Respir Drug Deliver 2002;8:197-206.
34. Schuschnig U, Urbishek M, Luber M, Selzer T, Tiffin N, Friedrich I, Keller M. Comparison of delivery efficiency in a nasal cast model of fluticasone propionate suspensions and a novel solution aerosolized via the PARI Vibrent. Respir Drug 2006;11:741-743.
35. Knoch M, Keller M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliver 2005;2(2):377-390.
36. Berlinski A, Waldrep JC. Effect of aerosol delivery system and formulation on nebulized budesonide output. J Aerosol Med 1997; 10(1):307-318.
37. Bouwman AM, Heijstra MP, Schaefer NC, Duiverman EJ, LeSouef PN, Devadeson SG. Improved efficiency of budesonide nebulization using surface-active agents. Drug Deliv 2006;13(5):357-363.
38. Amami A, Chrystyn H, Clark BJ, Abdelrahim ME, York P. Evaluation of supercritical fluid engineered budesonide powder for respiratory delivery using nebulisers. J Pharm Pharmacol 2009;61(12): 1625-1630.
39. Amami A, York P, Chrystyn H, Clark BJ. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. AAPS Pharm Sci Tech 2010;11:1147-1151.
40. Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, et al. The parmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol 2004; 44(1):67-72.
41. Shrewsbury SB, Bosco AP, Uster PS. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int J Pharm 2009;365(1-2):12-17.
42. Schuepp KG, Devadeson S, Roller C, Minocchieri S, Moeller A, Hamacher J, Wildhaber J. Aerosol delivery of nebulised budesonide in young children with asthma. Respir Med 2009;103(11): 1738-1745.
43. Basu K, Nair A, Williamson PA, Mukhopadhyay S, Lipworth B. Airway and systemic effects of soluble and suspension formulations of nebulized budesonide in asthmatic children. Ann Allergy Asthma Immunol 2009;103(5):436-441.
44. Williamson PA, Menzies D, Nair A, Tutuncu A, Lipworth BJ. A proof-of-concept study to evaluate the anti-inflammatory effects of a novel soluble cyclodextrin formulation of nebulised budesonide in patients with mild to moderate asthma. Ann Allergy Asthma Immunol 2009;102(2):161-167.
45. Nikander K, Wunderlich E. Output of budesonide suspension for nebulisation using different Pari jet nebulizer-compressor situations. J Aerosol Med 1997;10(1):100S
46. Barry PW, O'Callaghan C. Drug output from nebulizers is dependent on the method of measurement. Eur Respir J 1998;12(2):463-466.
47. Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med 1998;11(2):113-125.
48. Barry PW, O'Callaghan C. An in vitro analysis of the output of budesonide from different nebulizers. J Allergy Clin Immunol 1999; 104(6):1168-1173.
49. Luangkhot J, Jauernig J, Balcke A, Lintz FC, Liening-Ewert R, Stangl R, et al. Characterisation of salbutamol solution compared to budesonide suspensions consisting of submicron and micrometer particles in the PARI LC STAR and a new PARI electronic nebuliser (e-Flow). Drug Deliv Lungs XI 2000:14-17.
50. O'Callaghan C, Barry JW, Kantar A. Analysis of the output of beclomethasone dipropionate from different nebulisers. Riv Ital Pediatr 2000;26:821-824.
51. Fink JB, Uster P, Simon M. In vitro evaluation of budesonide nebulizing suspension with a novel aerosol generator. J Aerosol Med 2001;14:387.
52. O'Callaghan C, White J, Jackson J, Barry PW, Kantar A. The output of flunisolide from different nebulisers. J Pharm Pharmacol 2002;54(4):565-569.
53. Tservistas M, Sommer E, Knoch M, Hunziker G. Ultrasonic and perforated-mesh nebulizers: fundamental differences in function and performance. XIV Congress ISAM, Baltimore June 2003;P016.
54. Bosco AP, Dolovich MB. Improved aerosolization of suspensions using electronic micropump technology compared to conventional pneumatic nebulization. Chest 2004;126(Suppl):816S.
55. Fink JB, Simmons R. Nebulization of steroid suspension: an in vitro evaluation of the Aeroneb Go Nebulizer and the Pari LC Plus nebulizers. Chest 2004;126(Suppl):816S-817S.
56. Lintz F-C, von Opolski S, Hug M, Bucholski A, Keller M. Development of aqueous solubilized corticoid formulations for nebulization with a vibrating membrane nebulizer. AAPS Annual Meeting, Baltimore November 2004;1128M.
57. O'Callaghan C, White J, Jackson J, Barry PW, Kantar A. Delivery of nebulised budesonide is affected by nebuliser type and breathing pattern. J Pharm Pharmacol 2005;57(6):787-790.
58. Smaldone GC, Berg E, Nikander K. Variation in pediatric aerosol delivery: importance of facemask. J Aerosol Med 2005;18(3):354-363.
59. Vaghi A, Berg E, Liljedahl S, Svensson JO. In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per aerosol). Pulm Pharmacol Ther 2005;18(2): 151-153.
60. Zhou Y, Ahuja A, Irvin CM, Kracko D, McDonald JD, Cheng YS. Medical nebulizer performance; effects of cascade impactor temperature. Respir Care 2005;50(8):1077-1108.
61. Akapo S, Gupta J, Martinez E, McCrea C, Ye L, Roach M. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. Ann Pharmacother 2008;42(10): 1416-1424.
62. Bosco AP, Castillo MC, Luangvala MM. An in vitro evaluation of the aerosol equivalence of a generic budesonide inhalation suspension: a preliminary critique on equivalence compared to a proprietary budesonide inhalation suspension. Respir Drug Deliver 2008;2:619-622.
63. Bosco AP, Castillo MC, Luangvala. A novel submicron formulation of nebulized budesonide significantly improves the fine particle fraction of drug available for inhalation from various jet nebulizers compared to a marketed budesonide suspension. J Allergy Clin Immunol 2009;123(Suppl 1):S594.
64. Harris KW, Smaldone GC. Facial and ocular deposition of nebulized budesonide. Effects of face mask design. Chest 2008;133(2): 482-488.
65. Lieberman E, Bai T, Hatley R. Characterization of the performance of a new portable jet nebulizer system for the delivery of budesonide suspension for nebulization. Eur Respir J 2008;32:702S
66. O'Callaghan C, White JA, Jackson JM, Barry PW, Kantar A. Nebulisation of corticosteroids suspensions and solutions with a _2-agonist. J Pharm Pharmacol 2008;60(5):601-605.
67. Luangvala MM, Castillo MC, Bosco AP. A novel submicron aqueous colloid of budesonide significantly improves the aerodynamic particle sizing distribution of budesonide from various jet nebulizers compared to a marketed suspension (abstract). Am J Respir Crit Care Med 2009;179:A2769.
68. Berg E, Picard RJ. In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infants and child breathing patterns. Respir Care 2009;54(12):1671-1678.
69. Melani AS. Effects on aerosol performances of mixing of either budesonide or beclomethasone dipropionate with albuterol and ipratropium bromide. Respir Care 2011;56(3):319-326.
70. Finlay WH, Stapleton KW, Zuberbuhler P. Predicting regional lung dosages of a nebulized suspension: Pulmicort (budesonide). Particulate Sci Technol 1997;15:243-251.
71. Finlay WH, Stapleton KW. Undersizing of droplets from a vented nebulizer caused by aerosol heating during transit through an Andersen impactor. J Aerosol Sci 1999;30:105-109.
72. Jauernig J, Schuschnig U, Hug M, Keller M. Validation of a test set-up utilizing the 28.3 L/min Andersen Cascade Impactor (ACI) for the aerodynamic assessment of nebulized aqueous formulations. Respir Drug Delivery 2002;8:537-539.
73. Zhou Y, Ahuja A, Irvin CM, Kracko D, McDonald JD, Cheng YS. Evaluation of nebulizer performance under various humidity conditions. J Aerosol Med 2005;18(3):283-293.
74. Berg E, Bockstrom K, Dahlback M, Nerbrink O. Output and particle size distribution of Pulmicort suspension generated fromMAD2 and Pariboy jet nebulisers. J Aerosol Sci 1988;19(7):1093-1096.
75. Dahlback M. Behavior of nebulizing solutions and suspensions. J Aerosol Med 1994;1(7 Suppl):S13-S18.
76. Nikander K, Turpeinen M; Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med 1999;12(2):47-53.
77. Nicolini G, Panza I. Nebulization of inhaled corticosteroid viscous solutions by ultrasonic nebulizer. Allergy 2002;57(Suppl 73):339S.
78. Yoshiyama Y, Yazaki T, Arai M, Asai K, Kanke M. The nebulization of budesonide suspensions by a newly designed mesh nebulizer. In: Dalby RN, Byron PR, Peart J, Farr SF, editors. Respiratory drug delivery, 8th edition. Raleigh: Davis Horvood: 2002; 487-489.
79. Vecellio L. The mesh nebulized: a recent technical innovation for aerosol delivery. Breathe 2006;2:253-260.
80. Lødrup Carlsen KC, Nikander K, Carlsen K-H. How much nebulised budesonide reaches infants and toddlers? Arch Dis Child 1992; 67(9):1077-1079.
81. Nikander K. Drug delivery systems. J Aerosol Med 1994;1(7 Suppl): S19-S23.
82. Wennergren G, Nordvall SL, Hedlin G, Möller C, Wille S, Åsbrink-Nilsson E. Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Acta Paediatr 1996;85(2): 183-189.
83. Vikre-Jorgensen J, Agertoft L, Pedersen S. Dose titration of nebulized budesonide in young children. Pediatr Pulmonol 1997;23(4): 270-277.
84. Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child 1999;80(3):241-247.
85. Nikander K, Bisgaard H. Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. Pediatr Pulmonol 1999;28(3):187-93.
86. Nikander K, Turpeinen M, Wollmer P. Evaluation of pulsed and breath-synchronized nebulization of budesonide as a means of reducing nebulizer wastage of drug. Pediatr Pulmonol 2000;29(2): 120-126.
87. Nikander K, Agertoft L, Pedersen S. Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask and mouthpiece) on the inhaled mass of nebulized budesonide. J Asthma 200037(5):451-459.
88. Geller DE, Kesser KC, Janssens HM, Tiddens HA. Delivery of budesonide inhalation suspension (BIS) through an infant upper airway model (abstract). Am J Respir Crit Care Med 2003;167: A508.
89. Westbroek J, Saarlainen A, Laher M, O'Brien J, Barnacle H, Efthimiou J. Oral steroid-sparing effect of two doses of nebulized fluticasone propionate and placebo in patients with severe chronic asthma. Respir Med 1999;93(9):689-699.
90. Smaldone GC, McKenzie J, Cruz-Rivera M. Effects of nebulized volume on drug delivery: budesonide inhalation suspension (abstract). Am J Respir Crit Care Med 2000;161;(Suppl 3):A36.
91. Malpass J, Nagel M, Doyle C, Ali R, Avvakoumova V, Mitchell Y. A breath actuated jet nebulizer has dosimetric capability for a suspension formulation based on differing volume fill of medication as well as run time. Eur Respir J 2010;36(Suppl):54.
92. Rosenfeld M, Emerson J, Astley S, Joy P, Williams-Warren J, Standaert TA, et al. Home nebulizer use among patients with cystic fibrosis J Pediatr 1998;132(1):125-131.
93. Pujol MS, Menat C, Henon T, Jacquet M, Woronoff Lemsi MC. [Prescriptions of aerosol therapy. A survey of practices at the Besanc ̧on University Hospital]. Presse Med 2000;29:824-828. Article in French.
94. Salles M, deMonte M, Dubus JC, Diot P. [Nebulized corticosteroids and pediatricians: results of the NUAGES survey]. Arch Pediatr 2008;15:1520-1524. Article in French.
95. Gronberg S, Magnusson P, Bladh N. Chemical compatibility of budesonide inhalation suspension (Pulmicort) with other nebulization products (abstract). Am J Respir Crit Care Med 2001;163: A588.
96. McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004;38(6):967-972.
97. Kamin W, Schwabe A, Kramer I. Physicochemical compatibility of fluticasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions. Int J COPD 2007;2(4):599-607.
98. Bonasia PJ, McVicar WK, Williams B, Ong S. Chemical and physical compatibility of levoalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium. Respir Care 2008;53(12):1716-1722.
99. Bonasia P, Cook C, Cheng Y, Ong S. Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. Curr Med Res Opin 2007;23(10):2477-2483.
100. Berlinski A, Waldred JC. Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. J Aerosol Med 2006; 19(4):484-490.
101. DiBerardino, Scaglione F. Mixing albuterol and corticosteroid is not additive. Allergy 1999;54(9):1012-1013.
102. Brattsand R. Development of inhaled steroids: past, present and prospects. Respir Drug Deliver 2002;8:1-14.
103. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28(5):1042-50.
104. Winkler J, Hochhaus G, Derenderf H. How the lung handles drugs. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc 2004;1:356-363.
105. Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacological determinants of safety and efficacy and other clinical considerations. Paediatr Drugs 2007;9(3):185-194.
106. Kantar A, Mroueh S, Fiocchi A. A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. Allergy Asthma Proc 2007;28(6):571-587.
107. Dahlstrom K, Thorsson L, Larsson P, Nikander K. Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Ann Allergy Asthma Immunol 2003;90(2):226-232.
108. Schuepp KG, Devadeson S, Roller C, Wildhaber JH. A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children. Swiss Med Wkly 2004; 134(13-14):198-200.
109. Bisgaard H, Nikander K, Munch E. Comparative study of budesonide as a nebulized suspension vs pressurized meter-dose inhaler in adult asthmatics. Respir Med 1998;92(1):44-49.
110. Murphy K, Noonan M, Silkoff PE, Uryniak T. A 12-week multicenter, randomized, partially blinded, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaler corticosteroids with metered-dose or dry powder inhaler. Clin Ther 2007;29(6):1013-1026.
111. Poli G. Acerbi D. Comparison of the bioavailability and systemic effects of beclomethasone dipropionate suspension for nebulization and beclomethsone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. Respir Med 2003;97(Suppl B):S5-S9.
112. Haathela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, Budesonide in newly detected asthma N Engl J Med 1991;325(6):388-392.
113. Baker J, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide nebulizing suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999; 103(2):414-421.
114. Juniper EF, Kline PA, Vanzielghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142(4):832-836.
115. Waalkens HJ, van Essen-Zandvliet EE, Hughes MD, Gerritsen J, Duiverman EJ, Knol K et al. Cessation of long-term treatment with inhaled corticosteroid (budesonde) in children with asthma results in deterioration. Am Rev Respir Dis 1993;148(5):1252-1257.
116. Haathela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuiing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331(10):700-705.
117. Grimfeld A, Lesbros D, Ostinelli J, Caswell C. Long term study of nebulized budesonide in young children with moderate to severe asthma. Eur Respir J 1994;7(Suppl 18):27S
118. Pauwels RA, Lofdahl C-G, Postma DS, Tattersfield, O'Byrne P, Barnes P, Ullman A, for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. N Engl J Med 1997;337(20):1405-1411.
119. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109(3):410-418.
120. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, Pedersen SE, for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004; 170(8):836-844.
121. Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 2004;23(4):552-558.
122. Masoli M, Weatherall M, Holt S, Beasley R. Systematic review of the dose-response relation of inhaled fluticasone propionate. Arch Dis Child 2004;89(10):902-907.
123. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171(2):129-136.
124. Beasley R, Sterk PJ, Kerstjens HA, Decramer M. Comparative studies of inhaled corticosteroids in asthma. Eur Respir J 2001; 17(4):579-580.
125. Piacentini GL, Sette L, Peroni DG, Bonizzato C, Bonetti S, Boner AL. Double-blind evaluation of effectiveness and safety of flunisolide aerosol for treatment of bronchial asthma in children. Allergy 1990;45(8):612-616.
126. van Bever HP, Schuddinck L, Wojciechowski M, Stevens JW. Aerosolised budesonide in asthmatic infants: a double blind study. Pediatr Pulmonol 1990;9(3):177-180.
127. Ilangovan P, Pedersen P, Godfrey S, Nikander K, Noviski N, Warner JO. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993(3):68: 356-359.
128. DeBenedictis FM, Martinati LC, Solinas LF, Tuteri G, Boner AL. Nebulized flunisolide in infants and young children with asthma: a pilot study. Pediatr Pulmonol 1996;21(5):310-315.
129. DeBlic J, Delacourt C, LeBourgeois M, Mahut B, Ostinelli J, Caswell C, Scheinmann P. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol 1996;98(1):14-20.
130. Shapiro G, Bronsky EA, LaForce CF, Mendelson L, Pearlman D, Schwartz RH, Szefler SJ. Dose-related efficacy of budesonide administered via dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998;132(6): 976-982.
131. Kemp JP, Skoner DP, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999;83(3):231-239.
132. Melani AS, DiGregorio A. Four-week nebulized beclomethasone dipropionate in stable COPD patients with exertional dyspnoea. Monaldi Arch Chest Dis 1999;54(3):224-227.
133. Piacentini GL, Bodini A, Costella S, Vicentini L, Mazzi P, Suzuki Y, et al. Exhaled nitric oxide in asthmatic children exposed to relevant allergens: effect of flunisolide. Eur Respir J 2000;15(4): 730-734.
134. Berger WE, Qaqundah PY, Blake K, Rodriguez-Santana J, Irani AM, Xu J, Goldman M. Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr 2005;146(1):91-95.
135. Bodini A, Peroni DG, Zardini F, Corradi M, Alinovi R, Boner AL, Piacentini GL. Flunisolide decreases exhaled nitric oxide and nitrotyrosine levels in asthmatic children. Mediators Inflamm 2006; 2006(4):31919.
136. Paggiaro PL, Vagaggini B, DiFranco A, Zingoni M, Fano M, Biraghi M, on behalf of the COGNE Study group. Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease. Respiration 2006;73(5):603-606.
137. Papi A, Nicolini G, Baraldi E, Boner AL, Cutrera R, Rossi GA, Fabbri LM, on behalf of the Beclomethasone and Salbutamol Treatment (BEST) for Children Study group. Regular vs prn nebulized treatment in wheeze preschool children. Allergy 2009;64(10): 1463-1471.
138. Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999;104(4 Pt 2): 200S-209S
139. Cetinkaya F, Kayiran P, Memioglu N, Tarim OF, Eren N, Erdem E. Effects of nebulized corticosteroids on hypothalamic-pituitaryadrenal axis in young children with recurrent or persistent wheeze. Pediatr Allergy Immunol 2008;19:773-776.
140. Skoner DP, Szefler SJ, Welch M, Walten-Bowen K, Cruz-Rivera M, Smith JA. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol 2000;105(2):259-268.
141. Agertoft L, Pedersen S. Effect of long term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343(15):1064-1069.
142. Childhood Asthma Management Program Research Group. Longterm effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343(15):1054-1063.
143. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354(19): 1985-1997.
144. Murray CS, Woodcock A. Langley SJ, Morris J, Custovic A. Secondary prevention of asthma by the use of inhaled fluticasone proprionate in wheezy infants: double-blind randomized, controlled study. Lancet 2006;368(9537):754-762.
145. Cruz-Rivera M, Lyzell E, Fitzpatrick S. Low frequency of adverse events reported through postmarketing surveillance for Pulmicort Respules (budesonide inhalation suspension) in the US adult population. J All Clin Immunol 2002;109(Suppl 292):abstract 895.
146. Lyzell E, Cruz-Rivera M, Fitzpatrick S. Safety of Pulmicort Respules (budesonide inhalation suspension) in geriatric patients: postmarketing surveillance and clinical study data. J All Clin Immunol 2002;109(Suppl 292):abstract 894.
147. Greenberger PA, Patterson R. Beclomethasone dipropionate for severe asthma during pregnancy. Ann Intern Med 1983;98(4): 478-480.
148. Ericson A, Kallen B. Use of drugs during pregnancy-unique Swedish registration method that can be improved. Information from the Swedish Medical Products Agency 1999;1:8-11.
149. Kallen B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999;93:392-395.
150. Norjavaara E, Gerhardsson de Verdier M. Normal pregnancy outcomes in a population based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003;111(1):736-742.
151. Sangwan S, Gurses BK, Smaldone GC. Facemasks and facial deposition of aerosols. Pediatr Pulmonol 2004;37(5):447-452.
152. Szefler SJ, Fitzpatrick S, Cruz-Rivera M, Lyzell E. Lack of cataracts and other localized adverse events in children treated with nebulized Pulmicort Respules [Budesonide inhalation suspension] (abstract). Am J Respir Crit Care Med 2001;163:A589.
153. Peters SP. Safety of inhaled corticosteroids in the treatment of persistent asthma. J Nat Med Assoc 2006;98(6):851-861.
154. Pedersen S, Hansen OR. Dose-response relationships to nebulized budesonide in children with asthma (abstract). Am J Respir Crit Care Med 1997;155(2 part 2):A268.
155. Volovitz B, Soferman R, Blau H, Nussinovitch M, Varsano I. Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes. J Allergy Clin Immunol 1998; 101(4):464-469.
156. Lødrup Carlsen KC, Carlsen K-H, Nikander K, Leegaard J, Havnen J, Steen-Johnsen J, Winsness A. Nebulized budesonide after hospitalization for recurrent bronchial obstruction in children younger than 18 months. Pediatr Allergy Immunol 2001;12(3):159-165.
157. Price J, Lenney W, Duncan C, Green L, Flood Y, Daley-Yates P, et al. HPA-axis effects of nebulised fluticasone propionate compared with oral prednisolone in childhood asthma. Respir Med 2002;96(8):625-631.
158. Bisca N, Cernatescu I, Dragomir D, Iacomi A, Mirceau M, Orascanu D. Comparison of the efficacy and safety of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in paediatric patients with moderate to severe exacerbation of asthma. Respir Med 2003;97(Suppl. B):S15-S20.
159. Bousquet J, Meziane H, Chanez P, Mueser M, Umile A. The response of two different dosages of beclometasone dipropionate sus-pension for nebulization versus a standard dose of beclometasone dipropionate via a metered-dose inhaler on bronchoprovocation testing in adults with asthma. Respir Med 2003;97(Suppl B):S11-S14.
160. Grzelewska-Rzymowska I, Kroczynska-Bednarek J, Zarkovic J. Comparison of the efficacy and safety of high doses of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in steroid-dependent adults with moderate to severe asthma. Respir Med 2003;97(Suppl B):S21-S26.
161. Volovitz B, Nussinovitch M. Effect of high starting dose of budesonide inhalation suspension on serum cortisol concentration in young children with recurrent wheezing episodes. J Asthma 2003;40(6): 625-629.
162. DeBenedictis FM, Del Giudice MM, Vetrella M, Tressanti F, Tronci A, Testi R, Dasic G, FLIC12 Study Group. Nebulized fluticasone proprionate vs budesonide as adjunctive treatment in children with asthma exacerbation. J Asthma 2005;42(5):331-336.
163. Zielen S, Rose MA, Bez C, Jarisch A, Reichenbach J, Hofmann D. Effectiveness of budesonide nebulising suspension compared to disodium cromoglycate in early childhood asthma. Curr Med Res Opin 2006;22(2):367-373.
164. La Grutta S, Nicolini G, Capristo C, Bellodi SC, Rossi GA. Once daily nebulized beclomethasone is effective in maintaining pulmonary function and improving symptoms in asthmatic children. Monaldi Arch Chest Dis 2007;67(1):30-38.
165. Decimo F, Maiello N, Miraglia Del Giudice M, Amelio R, Capristo C, Capristo AF. High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. Int J Immunopathol Pharmacol 2009;22(2):363-370.
166. Storr J, Lenney CA, Lenney W. Nebulised beclomethasone dipropionate in preschool asthma. Arch Dis Child 1986;61(3):270-273.
167. Webb MCS, Milner AD, Hiller EJ, Henry RL. Nebulised beclomethasone dipropionate suspension. Arch Dis Child 1986;61(11): 1108-1110.
168. Pedersen W, Prahl P. Jet-nebulized beclomethasone dipropionate in the management of bronchial asthma. Topical steroids for asthmatic children younger than 4 years. Allergy 1987;42(2):272-275.
169. O'Callaghan C. Particle size of beclomethasone dipropionate produced by two nebulisers and two spacing devices. Thorax 1990; 45(2):109-111.
170. Wales D, Makker H, Kane J, McDowell P, O'Driscoll BR. Systemic bioavailability and potency of high-dose inhaled corticosteroids. A comparison of four inhaler devices and three drugs in healthy adult volunteers. Chest 1999;115(5):1278-1284.
171. Dempsey OJ, Humphreys M, Coutie WJ, Lipworth BJ. Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers. Eur J Clin Pharmacol 2001;57(9): 637-641.
172. Mendelson L, Cook D, Cruz-Rivera M, Fitzpatrick S, Smith JA. Twice-daily budesonide inhalation suspension in infants and children _4 and _ or _ 4 years of age with persistent asthma. J Asthma 2002;39(3):227-237.
173. Daugbjerg P, Brenoe E, Forchhammer H, Frederiksen B, Glazowski MJ, Ibsen Kaas K, et al. A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age. Acta Paediatr 1993; 82(6-7):547-551.
174. Bautista MS, Balderas J. The efficacy of combined inhaled steroids and _2 agonist in the treatment of acute asthma in children 6-18 years of age versus inhaled _2 agonist alone. Eur Respir J 1994; 7(Suppl 18):93S.
175. Sung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med 1998;5(3):209-213.
176. Tsai YG, Lee MY, Yang KD, Chu DM, Yuh YS, Hung CH. A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma. J Pediatr 2001;139(3):433-437.
177. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002;165(5):698-703.
178. Milani GKM, Rosario Filho NA, Riedi CA, Figueiredo BC. Nebulized budesonide to treat acute asthma in children. Jornal de Pediatria 2004;80(2):106-112.
179. Estrada-Reyes E, Del Rio Navarro BE, Rosas-Vargas MA, Nava-Ocampo AA. Co-administration of salbutamol and fluticasone for emergency treatment of children with moderate acute asthma. Paediatr Allergy Immunol 2005;16(7):609-614.
180. Nuhoglu Y, Atas E, Nuhoglu C, Iscan M, Ozcay S. Acute effect of nebulized budesonide in asthmatic children. J Invest Allerg Clin Immunol 2005;15(3):197-200.
181. Sekerel BE, Sackesen C, Tuncer A, Adalioglu G. The effect of nebulized budesonide treatment in children with mild to moderate exacerbations of asthma. Acta Paediatr 2005;94(10):1372-1377.
182. Gunen H, Hacievliyagil SS, Yetkin O, Golbas G, Cem L, In E. The role of nebulized budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007;29(4):660-667.
183. Camargo CA Jr., Rachelefsky G, Schatz M. Managing asthma exacerbations in the emergency department: Summary of the National Asthma Education and Prevention Program Export Panel Report 3 guidelines for the management of asthma exacerbations. J Allergy Clin Immunol 2009;124(Suppl 2):S5-S14.
184. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term highdose glucocrticoid treatment. Lancet 2000;355(9203):542-545.
185. Ducharme FM, Ochs HD, Resendes S, Zhang X, Mazer DB. A short burst of oral corticosteroid for children with acute asthma: is there an impact on immunity? Pediatric Allergy Immunology Pulmonogy 2010;23(4):243-252.
186. Mitchell CA, Alpers JH, Morton SM, Baggoley CJ, Croker WD, Walsh AJ, et al. Comparison of nebulized budesonide with oral prednisolone in the treatment of severe acute asthma. Eur Respir J 1995;8(Suppl):490S.
187. Francis P, Geelhoed G, Harris MA, Morton J, Efthimiou J, Barnacle H. Effect of nebulised fluticasone propionate 1 mg twice daily compared with oral prednisolone in pre-school chidren aged 48 months or less with an acute exacerbation of asthma. Eur Respir J 1997;10(Suppl 25):275S.
188. Winter JH, Dhillon DP, Winter JE, Feeney Y, Allen D, Maslen T. Effect of the early substitution of nebulised fluticasone propionate 2 mg bd for oral prednisolone 50 mg od in adults during the early recovery period of an acute exacerbation of asthma. Eur Respir J 1997;10:174S.
189. Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr 1999;88(8):835-840.
190. Matthews EE, Curtis PD, McLain BI, Morris LS, Turbitt ML. Nebulized budesonide verus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr 1999;88(8):841-843.
191. Manjra AI, Price J, Lenney W, Hughes S, Barnacle H. Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma. Respir Med 2000; 94(12):1206-1214.
192. Sano F, Cortez GK, Sole D, Naspitz CK. Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone. J Allergy Clin Immunol 2000;105(4):699-703.
193. Razi CH, Turktas I, Bakirtas A. Comparison of single 2000-_g dose treatment vs sequential repeated-dose 500-_g treatments with nebulized budesonide in acute asthma exacerbations. Ann Allergy Asthma Immunol 2008;100(4):370-376.
194. Wilson AM, McFarlane LC, Lipworth BJ. Systemic bioactivity profiles of oral prednisolone and nebulized budesonide in adult asthmatics. Chest 1998;114(4):1022-1027.
195. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 2005;353(16): 1711-1723.
196. Horvath G, Wanner A. Inhaled corticosteroids: effects of the airways vasculature in bronchial asthma. Eur Respir J 2006;27(1): 182-187.
197. Belda J, Margarit G, Martinez C, Bellido-Casado J, Casan P, Torrejón M, et al. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisolone in asthma exacerbations. Eur Respir J 2007;30(6):1143-1149.
198. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma. An evidence-based evaluation. Chest 2006;130(5):1301-1311.
199. Edmonds ML, Camargo CA Jr, Brenner B, Rowe BH. Inhaled steroids in acute asthma following emergency department discharge. Cochrane Database Syst Rev 2000;3:CD002316.
200. Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev 2003;(3):CD002308.
201. Volovitz B. Inhaled budesonide in the management of acute worsenings and exacerbations of asthma: a review of the evidence. Respir Med 2007;101(4):685-695.
202. Parkin PC, Saunders NR, Diamond SA, Winders PM, Macarthur C. Randomised trial spacer v. nebuliser for acute asthma. Arch Dis Child 1995;72(3):239-240.
203. Mason N, Roberts N, Yard N, Partridge MR. Nebulisers or spacers for the administration of bronchodilators to those with asthma attending emergency departments? Respir Med 2008;102(7):993-998.
204. Melani AS, Sestini P, Aiolfi S, Barbato N, Canessa P, DeAngelis G, et al; on behalf of the Associazione Italiana Pneumologi Ospedalieri (AIPO) Educational Group. GENebu Project: home nebulizer use and maintenance in Italy. Eur Respir J 2001;18(4):758-763.
205. Rachelefsky G. Inhaled corticosteroids and asthma control in children: assessing impairment and risk. Pediatrics 2009;123: 353-366.
206. PharmacyChecker. com. In the news: Pulmicort Respules price comparison: select product. http://www.pharmacychecker.com/ Strength.asp?drugId_57112 Accessed April 25, 2012.
207. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al; on behalf of the Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri (AIPO). Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105(6):930-938.
208. Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG; on behalf of the British Thoracic Society Audit Subcommittee of the Standards of Care Committee and the Royal College of Physicians of London. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002;57(2):137-141.
209. Krishnan JA, Demott M, McCoy JV, Chanmugam A, Rand CS. Nebulized beta2-agonist use in high-risk inner-city adults with asthma. J Asthma 2003;40(4):367-373.
210. Marcus P, Oppenheimer EA, Patel PA, Katz LM, Doyle JJ. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcome. Ann Allergy Asthma Immunol 2006;96(5): 736-743.
211. CamargoCAJr, Ramachandran S, Ryskina KL, Lewis BE. Legorreta AP. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am J Health Syst Pharm 2007;64(10):1054-1061.
212. McLaughlin T, Leibman C, Patel P, Camargo CA, Jr. Risk of recurrent emergency department visits or hospitalizations in children with asthma receiving nebulized budesonide inhalation suspension compared with other asthma medications. Curr Med Res Opin 2007;23(6):1319-1328.
213. Schuepp KG, Jauernig J, Janssens HM, Tiddens HA, Straub DA, Stangl R, et al. In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J Aerosol Med 2005;18(2): 225-235.
214. Amirav I, Newhouse MT, Minocchieri S, Castro-Rodriguez JA, Schuepp KG. Factors that affect the efficacy of inhaled corticosteroids for infants and young children. J Allergy Clin Immunol 2010; 125(6):1206-1211.